Navigation Links
VIVUS Reports Topline Findings From FORTRESS
Date:12/21/2011

and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >/=30 kg/m2), or overweight patients (BMI >/=27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
2. VIVUS Resubmits Qnexa NDA to the FDA
3. VIVUS Provides Regulatory Update on QNEXA
4. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
5. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
6. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
7. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
8. VIVUS to Present at Three Upcoming Investor Conferences in March
9. VIVUS Provides Regulatory Update on QNEXA NDA
10. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
11. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... IRVINE, Calif. , Aug. 31, 2015 /PRNewswire/ ... business and government, where regulations are often strict ... environment is driving a demand for professionals who ... interpret these regulations across a product lifecycle and ... organization. The University of California, Irvine Extension ...
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 2011 Reportlinker.com announces that a new market research ... Global Injectable Drug Delivery Market (2010 - 2015) ... KEY TAKE AWAYS * To ... its various sub-segments with respect to types of systems, ...
... Reportlinker.com announces that a new market research report ... European Markets for Minimally Invasive Spinal Devices ... The European minimally invasive spinal implant ... Rapid growth of the MIS interbody and MIS ...
Cached Medicine Technology:Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 2Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 3Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011 2
(Date:9/1/2015)... ... 2015 , ... September is Baby Safety Month, and Lightning Labels ... keep little ones' safety top of mind at all times. , Sponsored by the ... to the JPMA's Baby Safety Zone website, this year's theme is A Room with ...
(Date:9/1/2015)... ... September 01, 2015 , ... The premier online medical ... become a leader in podiatric, surgical and wound care conferences . The ... top national speakers at the podium and across the table during hands-on surgical ...
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, ... release of ten hours of new premium on-demand video Evidence Based Practice ... Athletic Trainers certified before 2014 must complete 50 CEUs before December 31, 2015, ...
(Date:8/31/2015)... , ... September 01, 2015 , ... ... eliminate chronic back pain – once required a long, arduous recovery. However, today’s ... stay, less pain, less blood loss and minimal muscle damage. These advantages of ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly ... Power and Influence by Modern Luxury’s The Atlantan Magazine. , This award ... as Kathy King. Her idea and vision to bring to Atlanta a true ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... reliability, improves information flow, facilitates documentation and, compliance, and ... ... outcomes., ... release of an enhanced NaviCare(R) WatchChild(R),solution, following receipt of marketing ...
... Additional Large Transactions in the Pipeline, LIVINGSTON, ... Board: MMGP) announced today that its wholly-owned,subsidiary, Genotec ... generates its sales from the distribution of its ... strategic,partners, has quoted on several large transactions for ...
... systems-based approach that combines comprehensive gene expression profiling with ... researchers to an important genetic marker that can help ... risk and will require more aggressive treatment, a research ... reports in the April 15, 2008, issue of the ...
... Anti-Tumor Activity, DALLAS, April 17 ... results from preclinical studies,ongoing at the prestigious ... monoclonal antibody. The new data, presented by ... Biochemistry,demonstrate that Angiolix has unusually high accumulation ...
... Eisai Corporation of,North America today announces the immediate ... Corporate Communications. In this newly created,position, Mr. Laverty ... Eisai,s corporate communications strategies and activities in the,United ... than 22 years of global corporate,product, policy and ...
... 17 A few years back, the,standard business card had ... side of plain vanilla paper stock, sometimes with,two-color printing to ... on both,sides of a BC in four-color process with a ... for 500 cards. This is a fraction,of what it cost ...
Cached Medicine News:Health News:Hill-Rom's NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care 2Health News:MM2 Group Provides Additional Quotes for New Venture in China 2Health News:Genome analysis reveals new protein associated with breast cancer progression 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 3Health News:Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications 2Health News:Your Business Card is a Powerful Marketing Tool 2
The Equator Convective Warmer incorporates LEVEL 1's unique, patented, temperature control technology to ensure delivery of the desired therapy to the patient....
The QuickVue Advance® G. vaginalis test is an enzyme activity test for use in the detection of Gardnerella vaginalis Proline IminoPeptidase(PIP) activity in vaginal fluid specimens from women su...
The Micro-Temp® II safely and consistently delivers a therapeutic level of localized heat using a pump, connecting hose and localized temperature therapy pad....
The Osom® Bvblue Test detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with Bacterial Vaginosis including Gardnerella, Bacteroides, Prevote...
Medicine Products: